BIOMAT Database Logo BIOMAT Database Logo

Cyclosporin A in the long-term treatment of psoriatic arthritis. 1996

F Porzio, and M Antonelli, and S Antonelli, and F Ceralli, and P Lanciani, and V Porzio, and G Minisola

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015535 Arthritis, Psoriatic A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor. Psoriasis Arthropathica,Psoriasis, Arthritic,Psoriatic Arthritis,Psoriatic Arthropathy,Arthritic Psoriasis,Arthropathies, Psoriatic,Arthropathy, Psoriatic,Psoriatic Arthropathies
D016572 Cyclosporine A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). Cyclosporin A,Ciclosporin,CsA-Neoral,CyA-NOF,Cyclosporin,Cyclosporine A,Neoral,OL 27-400,Sandimmun,Sandimmun Neoral,Sandimmune,CsA Neoral,CsANeoral,CyA NOF,OL 27 400,OL 27400
D018501 Antirheumatic Agents Drugs that are used to treat RHEUMATOID ARTHRITIS. Anti-Rheumatic Agent,Anti-Rheumatic Drug,Antirheumatic Agent,Antirheumatic Disease-Modifying Second-Line Drug,Antirheumatic Drug,DMARD,Disease-Modifying Antirheumatic Drug,Disease-Modifying Antirheumatic Drugs,Anti-Rheumatic Agents,Anti-Rheumatic Agents, Non-Steroidal,Anti-Rheumatic Drugs,Antirheumatic Disease-Modifying Second-Line Drugs,Antirheumatic Drugs,Antirheumatic Drugs, Disease-Modifying,Disease-Modifying, Antirheumatic Second-Line Drugs,Agent, Anti-Rheumatic,Agent, Antirheumatic,Anti Rheumatic Agent,Anti Rheumatic Agents,Anti Rheumatic Agents, Non Steroidal,Anti Rheumatic Drug,Anti Rheumatic Drugs,Antirheumatic Disease Modifying Second Line Drug,Antirheumatic Disease Modifying Second Line Drugs,Antirheumatic Drug, Disease-Modifying,Antirheumatic Drugs, Disease Modifying,Disease Modifying Antirheumatic Drug,Disease Modifying Antirheumatic Drugs,Disease Modifying, Antirheumatic Second Line Drugs,Drug, Anti-Rheumatic,Drug, Antirheumatic,Drug, Disease-Modifying Antirheumatic,Non-Steroidal Anti-Rheumatic Agents

Related Publications

F Porzio, and M Antonelli, and S Antonelli, and F Ceralli, and P Lanciani, and V Porzio, and G Minisola
Short-term "cyclosporin A" therapy for psoriatic arthritis.
January 1994, Acta dermato-venereologica. Supplementum,
F Porzio, and M Antonelli, and S Antonelli, and F Ceralli, and P Lanciani, and V Porzio, and G Minisola
Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis.
April 2002, Rheumatology international,
F Porzio, and M Antonelli, and S Antonelli, and F Ceralli, and P Lanciani, and V Porzio, and G Minisola
Psoriatic arthritis. Long term treatment with auranofin.
January 1986, Clinical rheumatology,
F Porzio, and M Antonelli, and S Antonelli, and F Ceralli, and P Lanciani, and V Porzio, and G Minisola
Long term treatment of psoriatic arthritis with infliximab.
November 2004, Annals of the rheumatic diseases,
F Porzio, and M Antonelli, and S Antonelli, and F Ceralli, and P Lanciani, and V Porzio, and G Minisola
Psoriatic arthritis treated with cyclosporin A.
December 1992, Allergie et immunologie,
F Porzio, and M Antonelli, and S Antonelli, and F Ceralli, and P Lanciani, and V Porzio, and G Minisola
Treatment of psoriatic arthritis with etanercept, methotrexate, and cyclosporin A.
February 2006, Clinical therapeutics,
F Porzio, and M Antonelli, and S Antonelli, and F Ceralli, and P Lanciani, and V Porzio, and G Minisola
Cyclosporin treatment in psoriatic arthritis: a cause of severe leg pain.
May 2003, Annals of the rheumatic diseases,
F Porzio, and M Antonelli, and S Antonelli, and F Ceralli, and P Lanciani, and V Porzio, and G Minisola
Stress fracture in long term methotrexate treatment for psoriatic arthritis.
August 2001, Annals of the rheumatic diseases,
F Porzio, and M Antonelli, and S Antonelli, and F Ceralli, and P Lanciani, and V Porzio, and G Minisola
DAPSA, DAS28 and MDA predict long-term treatment regime in psoriatic arthritis. The Swedish Early Psoriatic Arthritis Cohort.
January 2017, Clinical and experimental rheumatology,
F Porzio, and M Antonelli, and S Antonelli, and F Ceralli, and P Lanciani, and V Porzio, and G Minisola
Cyclosporin A in psoriatic arthritis: an open study.
August 1990, Annals of the rheumatic diseases,
Copied contents to your clipboard!